Trevi Therapeutics updates pipeline timelines: CORAL at 50% enrolled, SSRE in Dec, RIVER topline Q1 2025

Trevi Therapeutics, Inc.

Phase 2b CORAL trial for chronic cough in IPF enrolled 50% of target (N=160); SSRE expected December 2024.
SSRE may maintain current size, upsize within pre-specified range, or evaluate for futility; topline H1 2025 if unchanged.
Human Abuse Potential study completed dosing; topline results expected December 2024.
Phase 2a RIVER trial for refractory chronic cough enrolled planned sample size; topline results now expected Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.